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Abstract
The protozoan Plasmodium vivax is responsible for 42% of all cases of malaria outside Africa. The parasite is
currently largely restricted to tropical and subtropical latitudes in Asia, Oceania, and the Americas. Though, it
was historically present in most of Europe before being finally eradicated during the second half of the 20th
century. The lack of genomic information on the extinct European lineage has prevented a clear understanding
of historical population structuring and past migrations of P. vivax. We used medical microscope slides pre-
pared in 1944 from malaria-affected patients from the Ebro Delta in Spain, one of the last footholds of malaria
in Europe, to generate a genome of a European P. vivax strain. Population genetics and phylogenetic analyses
placed this strain basal to a cluster including samples from the Americas. This genome allowed us to calibrate a
genomic mutation rate for P. vivax, and to estimate the mean age of the last common ancestor between
European and American strains to the 15th century. This date points to an introduction of the parasite during
the European colonization of the Americas. In addition, we found that some known variants for resistance to
antimalarial drugs, including Chloroquine and Sulfadoxine, were already present in this European strain,
predating their use. Our results shed light on the evolution of an important human pathogen and illustrate
the value of antique medical collections as a resource for retrieving genomic information on pathogens from the
past.
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Introduction
Malaria is a leading cause of infectious disease, responsible for
an estimated 200 million infections annually, and around
429 000 fatal cases (World Health Organisation 2017). The
disease is caused by several species of parasitic protozoans
from the genus Plasmodium, which are transmitted by vari-
ous species of mosquitoes from the genus Anopheles. Two
species in particular—Plasmodium falciparum and
Plasmodium vivax—are responsible for the majority of hu-
man infections worldwide. Although P. falciparum causes
99% of malaria deaths globally, P. vivax is the etiological agent
of 42% of all cases outside of Africa (Gething et al. 2011; World
Health Organisation 2017).
Today, endemicity of the genus Plasmodium is restricted to
tropical and subtropical latitudes, spanning large regions of
East and South East Asia, sub-Saharan Africa, Central and
South America, and Melanesia (Battle et al. 2012, 2019;
Howes et al. 2016; Weiss et al. 2019). However, malaria was
historically present in most of Europe, from the
Mediterranean to the southern shores of the Baltic Sea, and
from southern Britain to European Russia (Hulden et al.
2005). Malaria was eradicated from all European countries
during the second half of the 20th century (Hay et al.
2004), with Spain being one of its last footholds from which
it was only declared officially eradicated in 1964 (Pletsch
1965). Nevertheless, even though Plasmodium is currently
largely absent from Europe, its potential re-emergence has
been identified as a plausible consequence of climate change
(Petersen et al. 2013; Zhao et al. 2016).
Whilst historically being described as the “benign” form of
malaria, P. vivax is increasingly recognized as a significant
cause of disease and mortality (Tjitra et al. 2008; Price et al.
2009; Lacerda et al. 2012; Baird 2013). In stark contrast to
P. falciparum, P. vivax is capable of producing recurrent ma-
laria episodes from a single infection due to its resistant latent
forms known as hypnozoites (Gonzalez-Ceron et al. 2013;
Adekunle et al. 2015). This capacity also allows P. vivax to
maintain itself in temperate climates, resting in a dormant
state in the cold months when anopheline populations are in
diapause, and creating a persistent presence of parasite res-
ervoirs which can facilitate widespread transmission and re-
current long-term infections (Krotoski 1985; Gething et al.
2011; White 2011). Low parasite densities of P. vivax in mixed
infections (Mayxay et al. 2004; Moreira et al. 2015) and the
suggested high proportion of hypnozoite-derived clinical in-
cidence (Price et al. 2009; Howes et al. 2016) means the global
prevalence of P. vivax is likely systematically underestimated
in comparison with the better-studied P. falciparum.
Plasmodium vivax is widely considered to have emerged in
sub-Saharan Africa, a region in which it is now at low prev-
alence (Liu et al. 2014; Gunalan et al. 2018; Twohig et al. 2019).
From there, it is thought to have spread globally through a
complex pattern of migration events by hitchhiking with its
human host, as humans moved out of Africa (Culleton et al.
2011; Hupalo et al. 2016). The analysis of a geographically
diverse data set of 941 P. vivax mitochondrial DNA
(mtDNA) genomes detected genetic links between strains
from the Americas to those from Africa and South Asia, al-
though potential contributions from Melanesia into the
Americas were also identified (Rodrigues et al. 2018).
However, the role of the worldwide colonial expansion of
European countries in the global dispersal of P. vivax remains
largely unknown, mainly due to the lack of available se-
quenced nuclear genomes from now-extinct European
strains.
The recent discovery of a set of historic microscope slides
with bloodstains from malaria-affected patients provides ma-
jor opportunities to shed light on the evolution of P. vivax.
The slides were prepared between 1942 and 1944 in the Ebro
Delta (Spain), an area where the disease was transmitted by
the mosquito species Anopheles atroparvus, a member of the
Anopheles maculipennis complex—still very common in the
region—and provided the first retrieval of genetic material
from historical European P. vivax (Gelabert et al. 2016) as well
as a partial P. falciparum genome (de-Dios et al. 2019). The
complete mtDNA genome of this sample showed a close
genetic affinity to the most common strains of present-day
South and Central America, suggesting their introduction
into the Americas was linked to Spanish colonial-driven trans-
mission of European strains. However, mtDNA is a maternally
inherited single locus and, in comparison with the entire ge-
nome, has limited power to reconstruct complex evolution-
ary histories.
In this paper, we extend these previous findings, by report-
ing the complete genome of an extinct European P. vivax
obtained from the historical Ebro Delta microscope slides.
Together with the recent publication of a more accurately
annotated P. vivax reference genome (PvP01) (Auburn et al.
2016), this European genome provides new opportunities to
resolve the historical dispersals of this parasite using genome-
wide data. The availability of this complete genome also
allows direct estimation of an evolutionary rate for P. vivax,
making it possible to date the clustering of the historic
European strain with modern global strains. Furthermore, it
enables us to ascertain the presence of some resistance alleles
prior to the introduction of most anti-malaria drugs. This
information is critical for further investigations into the evo-
lution of the parasite, as well as predicting future emergences
of drug-resistance mutations.
Results
We generated shotgun Illumina sequence data from four ar-
chival blood slides derived from malaria patients sampled
between 1942 and 1944 in Spain’s Ebro Delta. The majority
of reads that mapped to P. vivax (89.09%) derived from a
single slide dated to 1944. In total, 481,245 DNA reads
(0.44% of the total reads generated) mapped to P. vivax, yield-
ing a composite genome, we term Ebro-1944, at 1.4 cover-
age (1.28 deriving from the newly analyzed 2017 slide), and
spanning 66.42% of the (PvP01) reference. The mtDNA ge-
nome was recovered at 32 coverage (supplementary figs. 1–
5 and tables 1–3, Supplementary Material online). Although
working with low coverage ancient genomes is challenging,
the fact that our genome is haploid and displays low levels of
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postmortem sequencing errors suggests it can be reliably used
in most evolutionary analyses.
To explore the phylogeographic affinities of the eradicated
European strain we performed several population genomics
analyses (supplementary figs. 6–12 and table 4,
Supplementary Material online). A principal component
analysis (PCA) applied to a global data set of P. vivax showed
strong geographic structure, with clusters separating 1) South
East Asian/East Asian strains; 2) Oceanian strains (those from
Malaysia were placed between the two clusters); 3) Indian
and Madagascan strains; and 4) those sampled from Central/
South America (fig. 1a and b). The European sample (labeled
Ebro-1944) falls at one end of the latter cluster, on an axis of
variation shared by strains from Mexico, Brazil, Colombia, and
Peru.
Model-based clustering implemented in an unsupervised
ADMIXTURE analysis (fig. 1c and supplementary fig. 8,
Supplementary Material online) provided qualitatively con-
sistent inferences to those observed by PCA, with one ances-
try component maximized in Oceanian samples, two largely
shared by East and South East Asian samples, and three fur-
ther components which largely differentiate samples from
South and Central America. The ancestry of Ebro-1944 is
mostly modeled by the three components identified in sam-
ples from South America (56% Colombia-like and 22%
Peru-like) and Central America (12% Mexico-like), although
a minor proportion of ancestry is shared with both South East
Asian (5%) and Oceanian (5%) samples.
To formally test these suggested relationships, we calcu-
lated f4 statistics (Patterson et al. 2012) of the form
(Plasmodium cynomolgi, Ebro-1944; X, Y), where X and Y
are tested for all combinations of samples from 15 worldwide
locations (fig. 2). Plasmodium cynomolgi was selected as an
outgroup as it represents the closest nonhuman infecting
Plasmodium species (Tachibana et al. 2012). This statistic is
designed to quantify the covariance in allele frequency differ-
ences between P. cynomolgi and Ebro-1944 relative to P. vivax
from sampled worldwide locations (X and Y), with a more
positive f4 value indicating a closer relationship of Ebro-1944
to samples from Y relative to X. Using this framework and
testing all possible topological relationships, Ebro-1944 was
found to share significantly more derived alleles with Central
and Southern American strains compared with those sam-
pled from South East and East Asia (fig. 2 and supplementary
fig. 9, Supplementary Material online). These results collec-
tively support the presence of a cline of ancestry stretching
FIG. 1. (a) PCA of the historic Ebro-1944 sample together with a geographically diverse set of modern Plasmodium vivax strains. (b) Example
microscopy slide stained with the blood of patient’s infected with malaria from the Ebro Delta, Spain, in the 1940s. (c) Unsupervised ADMIXTURE
clustering analysis at K ¼ 6. Samples are arranged by geographic region and colored as in (a).
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from Europe to the Americas, with our eradicated European
strain showing strong phylogenetic affinity to modern P. vivax
samples from Mexico, Brazil, and Peru.
Additional evidence was also obtained using an unrelated
method designed to cluster global samples based on inferred
patterns of haplotype sharing (Lawson et al. 2012).
Considering haplotype variation rather than allele frequency
differences increases power to resolve fine-scale genetic struc-
ture (Leslie et al. 2015) and is robust to potential single nu-
cleotide polymorphism (SNP) calling errors (Conrad et al.
2006). Haplotype-based clustering grouped Ebro-1944 with
samples from South and Central America (fig. 3a). This result
was robust to the inclusion of different samples in the data
set, to moderate imputation, and remained consistent when
either uncorrelated sites or linked sites were considered (sup-
plementary figs. 10–12, section 4, and methods,
Supplementary Material online).
Given the strong phylogeographic affinity of Ebro-1944 to
P. vivax currently in circulation in the Americas, we tested
whether the divergence of Ebro-1944 from American strains is
better explained by a deep split, for example at the time of the
original human settlement of the Americas at least 15,000
years ago, or is more consistent with a recent introduction to
the Americas. Genomes obtained from historical or ancient
materials provide unique opportunities to calibrate phyloge-
netic trees, by directly associating sampling dates with the
sequences representing the phylogeny tips (terminal nodes).
These in turn enable inference of divergence times and mu-
tation rates without the need for any other age-related ex-
ternal data (Rieux and Balloux 2016). Therefore, to infer the
temporal relationship of Ebro-1944 to strains from the
Americas, we included our historic sample together with 15
closely related publicly available genomes sampled over a
range of time periods (supplementary table 5,
Supplementary Material online). We selected strains predom-
inantly from the Americas, with three additional genomes
included from India, Myanmar, and North Korea to root
the topology and increase the time span of our data set.
To account for the possible confounding effect of genetic
recombination, we filtered the resulting alignment for a set of
high confidence congruent SNPs. Specifically, we removed all
homoplasic that is SNPs in the alignment in conflict with the
maximum parsimony phylogeny (see Materials and
Methods). This approach identifies, with no required prior
knowledge, regions of the genome that are hypervariable,
deriving from recombination or mixed infections, as well as
filtering SNPs which may have been erroneously called due to
low sequence quality or postmortem damage. The resulting
alignment exhibited a significant positive correlation between
the root-to-tip phylogenetic distances of a maximum likeli-
hood phylogeny and the time of sampling, indicating the
presence of detectable temporal accumulation of de novo
mutations within the timescale of our data set (fig. 3b, sup-
plementary fig. 13, Supplementary Material online).
Mutation rates were subsequently estimated using the
Bayesian phylogenetic tool BEAST2 (Bouckaert et al. 2014)
testing a range of demographic and clock rate priors. We
estimated the mutation rate over the tested alignment to
5.57E7 substitution/site/year [HPD 95% 2.75E8–1.06E6].
Though a broad estimate, we obtained low values (<0.15)
of the standard deviation of the uncorrelated log-normal re-
laxed clock (ucld.stdev), suggesting little variation in rates
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FIG. 2. f4-Values inferred under the test relationship (Plasmodium cynomolgi, Ebro-1944; Papua New Guinea [PNG], Y), where Y iterates through
the geographic sampling locations of our included strains. The color scale provides the value of the f4 statistic with the significance (absolute z
score), assessed through block jackknife resampling, provided by the circle size. A more positive f4 value indicates a closer relationship of Ebro-1944
to Y relative to PNG.
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between branches. This approximation enabled us to infer
that the historical Ebro-1944 genome shares a common an-
cestor with strains in the South-American cluster dating to
the 13th–19th centuries (mean 1415; HPD 95% 1201–1877
CE) (fig. 3c, supplementary fig. 14 and table 6, Supplementary
Material online).
A number of mutations conferring resistance to antima-
larial drug treatments developed in the later decades of the
20th century have been identified in P. vivax. For instance,
mutations in the pvdhfr gene are known to be involved in
resistance to pyrimethamine (de Pecoulas et al. 1998;
Imwong et al. 2001, 2003; Huang et al. 2014) whilst muta-
tions at the pvdhps gene confer resistance to sulfadoxine
(Korsinczky et al. 2004; Menegon et al. 2006;
Hapuarachchi et al. 2009). Other genes, including pvmdr1
(Brega et al. 2005; Sa et al. 2005; Barnadas, Tichit, et al.
2008), CRT (Suwanarusk et al. 2007), or pvmrp1 (Dharia
et al. 2010), are thought to be involved in chloroquine
resistance. Plasmodium vivax populations also exhibit
high genetic diversity in genes related to immune evasion
and host infectivity, including MSP10, MSP7, and CLAG.
We annotated 4,800 SNPs in the Ebro-1944 genome (sup-
plementary table 7, Supplementary Material online). Of
these, 1,195 are missense mutations, which represent
60.6% of the genic mutations. Similar ratios have been
reported in other P. vivax strains (Hupalo et al. 2016;
Pearson et al. 2016; de Oliveira et al. 2017).
Ebro-1944 carries the derived allele in three SNPs located in
genes functionally associated with antimalarial drug resis-
tance. Two of these, Val1478Ile and Thr259Arg (Dharia
et al. 2010; de Oliveira et al. 2017) are in the pvmdr1 gene
and another, Met205Ile (Hapuarachchi et al. 2009), occurs in
the pvdhps gene (supplementary tables 8 and 9,
Supplementary Material online). We also identified a previ-
ously undescribed mutation (Leu623Arg) in CLAG, a gene
associated with host infectivity (Gupta et al. 2015). In addi-
tion, we screened multiple loci (N¼ 516) that have previously
been reported to exhibit strong signals of recent natural se-
lection in a geographically diverse set of modern P. vivax
samples (Hupalo et al. 2016). Some of these regions
FIG. 3. (a) CHROMOPAINTER’s inferred counts of matching DNA genome wide that each of the 104 inferred clusters (columns) is painted by each
of the 104 clusters (rows). The tree at top shows fineSTRUCTURE’s inferred hierarchical merging of these 104 clusters and the colors on the axes
give the continental region and population to which strains in each cluster are assigned. Ebro-1944 is depicted in black and clusters with the sample
from Peru and Brazil. (b) Root-to-tip distances of our included Plasmodium vivax strains correlated with the date of isolation. The regression was
significant following 1,000 random permutations of sampling date. (c) Tip-dated maximum clade credibility phylogenetic tree obtained with
BEAST 2. The mean posterior probability for the time to the most recent common ancestor between the historical European strain and the
American strains is indicated. Tips are colored as in fig. 1a.
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encompass genes previously known to be involved in anti-
malarial drug resistance, including three with strong experi-
mental validation of resistance phenotypes: pvmdr1, dhfr, and
dhfps (Haldar et al. 2018). Our historical genome has 355 of
these positions covered by at least two reads, of which Ebro-
1944 exhibits the ancestral allele in 349 (supplementary table
10, Supplementary Material online). Therefore, only six of the
355 derived variants with high FST values (including the pre-
viously mentioned Met205Ile variant at pvdhps gene) were
present in the historical European sample, suggesting a rapid
accumulation of resistance conferring mutations in more re-
cent strains.
Discussion
Our genome-wide analyses of a historic European P. vivax
nuclear genome confirm the inference, previously based solely
on mtDNA, that extinct European P. vivax are closest genet-
ically to strains currently in circulation in Central and South
America (Gelabert et al. 2016). Historical accounts of the
presence of tertian (P. vivax) malaria in Europe date to at
least Classical Greece (De Zulueta 1973; Carter 2003), suggest-
ing that the most parsimonious explanation is an introduc-
tion of P. vivax from Europe into the Americas and not the
other way around. A migration event from Europe into the
Americas is further supported by the European Ebro-1944
P. vivax strain falling as an out group to all the strains from
the Americas (fig. 3c). Finally, the estimated mean age of
divergence in the 15th century between Ebro-1944 and
strains in circulation in the Americas (fig. 3c) is consistent
with an introduction of P. vivax malaria into the Americas by
European colonists.
Whether any agent of malaria was present in the Americas
prior to European contact (1492) has been debated (Carter
2003; Hume 2003; de Castro and Singer 2005). It is relatively
unlikely that any malarial parasites would have survived the
journey across the Bering strait during the initial peopling of
the Americas some 15,000 years ago (Waters et al. 2018) due
to the absence of mosquito vectors at these high latitudes
allowing the parasites to fulfill their life cycles (Tanabe et al.
2010). However, accounts of the therapeutic use by Incas of
cinchona tree bark, from which quinine derives, have been
interpreted as suggestive of malaria being present in the
Americas pre-Columbian contact (Escardo 1992). Though,
its use may have been motivated by the effectiveness of qui-
nine in the treatment of other fever-causing illnesses.
Older split times between P. vivax lineages from the
Americas and the rest of the world than the one we inferred
based on whole-genome sequences have been suggested
from the analysis of mtDNA genomes (Taylor et al. 2013;
Rodrigues et al. 2018). Though, we note that, even when
accounting for the posterior uncertainty around our inferred
mutation rate, all possible temporal estimates place the split
time between the European and American strains as incom-
patible with an introduction of P. vivax into the Americas
alongside the first humans to colonize the continent. Our
results are therefore highly supportive of an introduction of
P. vivax to the Americas during the European colonial period,
with our range also consistent with the transatlantic slave
trade between Africa and Spanish and Portuguese-run ports
in Central and South America. Our analyses of the nuclear
genome further point to a minor genetic component in
American strains shared with strains from Madagascar,
India, and Sri Lanka (figs. 1c and 3a). We interpret this as
likely evidence for secondary genetic introgression into the
American P. vivax population by lineages from different
regions of the world, which would be consistent with the
high P. vivax mtDNA diversity previously described in the
Americas (Taylor et al. 2013; Hupalo et al. 2016; de Oliveira
et al. 2017; Rodrigues et al. 2018).
In this work, we restricted the phylogenetic dating to the
migration of P. vivax into the Americas. There is currently no
consensus over the age of the most recent common ancestor
of all extant, worldwide P. vivax strains. Some previous esti-
mates inferred the origin of P. vivax to around 5,000 or 10,000
years ago (Carter 2003; Leclerc et al. 2004; Lim et al. 2005),
whereas far older dates have been proposed, including
45,000–81,000 years (Escalante et al. 2005) or even 53,000–
265,000 years (Mu et al. 2005). An extrapolation of our in-
ferred evolutionary rates to the global diversity of extant
P. vivax strains would point to a recent origin for the parasite.
Though, formally estimating the age of P. vivax through a
phylogenetic “tip-dating” approach poses a series of analytical
challenges. For example, the homoplasy screening method we
employed to exclude homoplasic caused by mixed infections
and likely genetic recombination is currently not computa-
tionally tractable for a data set comprising a large number of
globally sourced whole P. vivax genomes. Possible solutions to
this problem may arise through optimization of sequencing
protocols to generate higher quality Plasmodium whole-ge-
nome sequences together with the development of down-
stream bioinformatics approaches designed to propagate
genotype calling uncertainty and deconvolve mixed infec-
tions (Zhu et al. 2018). This should be aided by the generation
of further high-quality reference genomes across the
Plasmodium genus, for example using long-read sequencing
technology (Auburn et al. 2016; Pasini et al. 2017; Gilabert
et al. 2018; Otto et al. 2018).
Reconstruction of the phylogeographic relationships be-
tween P. vivax strains is complicated further by mounting
evidence for the zoonotic potential of P. vivax and P. vivax-
like strains; with host-jumps likely having occurred several
times in the parasite’s evolutionary history (Prugnolle et al.
2013; Liu et al. 2014, 2017; Loy et al. 2017). The discovery of
the platyrrhine protozoa, Plasmodium simium, as morpholog-
ically (Ott 1967) and genetically (Leclerc et al. 2004; Escalante
et al. 2005; Lim et al. 2005) indistinguishable from P. vivax
suggests very recent host transfers between South American
monkeys and humans; in some cases responsible for the in-
cidence of zoonotic malarial disease (Brasil et al. 2017; Buery
et al. 2017). This raises important questions as to what should
be considered as the host-range of P. vivax and queries what
species delineation should be applied in comparative geno-
mics studies. Recurrent host jumps of P. vivax lineages into
humans from animal reservoirs, with subsequent demo-
graphic expansions and possible lineage replacements, may
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point to a recent age for the ancestor of all extant P. vivax
strains, despite now-extinct lineages of the parasite having
likely plagued humans for far longer.
Malaria is widely believed to have exerted one of the stron-
gest selective forces on the human genome (Hedrick 2012).
Well-known examples of selection against malaria include
protective mutations at the HBB gene that give rise to resis-
tant isoforms of proteins such as HbS and HbE in African and
Asian populations, respectively, and mutations at the G6PD
gene which are broadly spread in African populations and are
also present in the Mediterranean (Tishkoff et al. 2001;
Kwiatkowski 2005; Howes et al. 2012). One of the best-
known examples of directional selection is the FY*0 Duffy
blood negative genotype that confers resistance to P. vivax
which is close to fixation in sub-Saharan Africa but essentially
absent in other regions of the world. The protein is the key
invasion receptor for the human malarial parasites P. vivax,
Plasmodium knowlesi, and the simian malarial parasite
P. cynomolgi (Kosaisavee et al. 2017). Exposure to an ancestor
of P. vivax may have led to the sweep of the FY*0 allele in sub-
Saharan Africa some 40,000 years ago and may represent the
fastest known selective sweep for any human gene
(McManus et al. 2017).
Though, given the relatively mild clinical symptoms of
modern P. vivax, it is not inconceivable that the selective
forces that led to the fixation of the FY*0 allele in sub-
Saharan Africa may have been caused by another malaria
parasite. A further complicating factor stems from increasing
evidence accumulating for previously unrecognized endemic
P. vivax circulating in human populations from sub-Saharan
Africa, including in Duffy-negative hosts (Gunalan et al. 2018;
Twohig et al. 2019). The presence of endemic P. vivax malaria
in sub-Saharan Africa may suggest that the FY*0 allele may
confer only partial protection against P. vivax malaria. Our
results, which point to a recent, post-European contact ex-
posure of Native American populations to P. vivax malaria,
would not have had the time to drive the emergence and
spread of resistance alleles comparable with those observed in
Africa and Europe. Consistently, to date, no known malaria-
resistance variants have been identified in Native Americans
(Hume 2003; Kwiatkowski 2005).
Irrespective of its role in the past, the rapid spread of
P. vivax strains resistant to antimalarial drugs is an area of
increasing concern. Initially, chloroquine was established as
the main therapy against P. vivax infections in 1946 (Most and
London 1946; Baird 2004). It was a well-tolerated and effective
treatment until resistance appeared in the late 1980s and
spread through the entirety of the endemic range of
P. vivax (Rieckmann et al. 1989). However, despite extensive
drug resistance within present-day P. vivax populations,
caused by a variety of resistance loci in multiple genes
(Hupalo et al. 2016), chloroquine–primaquine combined
therapy remains the most commonly prescribed treatment
(Phillips et al. 1996), as few other therapeutic strategies are
available. The increase in frequency of drug resistant strains is
thus a significant public health threat with major human and
economic costs.
Our historical sample predates the use of all anti-malaria
drugs, with the exception of quinine which was introduced in
Europe as early as 1683 (Achan et al. 2011). Ebro-1944 carries
the ancestral allele in an overwhelming number of SNPs
(99.3%) known to have undergone selection in modern
strains, including those associated with drug resistance in
genes such as DHFR-TS (de Pecoulas et al. 1998;
Leartsakulpanich et al. 2002; Imwong et al. 2003; Ganguly
et al. 2014; Huang et al. 2014) and MDR1 (Brega et al. 2005;
Sa et al. 2005; Barnadas, Ratsimbasoa, et al. 2008; Orjuela-
Sanchez et al. 2009) (supplementary tables 8 and 9,
Supplementary Material online). Conversely, Ebro-1944 car-
ries three variants in the pvmdr1 and pvdhps genes that are
plausible drug-resistance candidates against sulfadoxine and
chloroquine. The presence of these alleles in Ebro-1944 might
reflect standing variation in historical P. vivax populations for
alleles providing resistance to modern antimalarial drugs.
Alternatively, these could have been selected for by the his-
torical use of quinine.
Our study stresses the value of old microscopy slides
and, more generally, of antique medical collections, as a
unique and under-used resource for retrieving genomic
information on pathogens from the past, including erad-
icated strains that could not be studied from contempo-
rary specimens. For example, in addition to the results
reported here, we also retrieved a partial P. falciparum
genome from the same set of slides, which allowed us
to demonstrate a stronger phylogeographic affinity of
the extinct European P. falciparum lineage to present-
day strains in circulation in central south Asia, rather
than Africa (de-Dios et al. 2019). We note that the slides
we analyzed here were stained but not fixed and it
remains to be explored what additional DNA damage is
exerted by different fixation methods. In addition, our
slides date from the years 1942 to 1944; however, it is
likely that older slides are available in both public and
private collections given the popularity of microscopy
in Victorian times. A future objective will be to ascertain
if massive genomic data retrieval can be achieved from
even older microscopy slides.
There is also potential to retrieve ancient Plasmodium
sequences directly from archaeological specimens. The
recent retrieval of P. falciparum sequences from ancient
Roman human skeletal remains (Marciniak et al. 2016)
demonstrates this approach is technically feasible, and
as P. vivax infection is more prevalent than
P. falciparum, it is plausible that further ancient strains
from osteological material could be reported in the near
future. An additional possibility would be to directly re-
trieve Plasmodium sequences from Anopheles remains
preserved in ancient lake sediments or in museum collec-
tions. The generation of additional historical sequences—
both from Europe and from the Americas—together with
an increased sequencing effort of extant P. vivax strains
from under-sampled areas is our best hope to reconstruct
the evolutionary history of this major parasite in more
detail.
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Materials and Methods
Samples
The slides analyzed here belong to the personal collection of
the descendants of Dr Ildefonso Canicio, who worked in the
antimalarial center established by the Catalan Government at
Sant Jaume d’Enveja (Ebro Delta, Spain) in 1925. Four slides
were analyzed, three of them included in a previous study
(Gelabert et al. 2016). The new sample was a drop of blood
from a double slide, stained with Giemsa (fig. 1b).
DNA Extraction
DNA extraction was performed by incubating the slide with
20 ml of extraction buffer (10 mM Tris-HCl [pH 8], 10 mM
NaCl, 5 mM CaCL, 2.5 mM EDTA, 1% SDS, 1% Proteinase K,
0.1% DTT [w/v]) in an oven at 37 C for 20 min for a total of
three rounds. The resulting dissolved bloodstain and buffer
were collected in a 1.5 ml Lobind Eppendorf and then incu-
bated for 1 h at 56 C. This was subsequently added to 10
volume of modified binding buffer (Allentoft et al. 2015) and
passed through a Monarch silica spin column (NEB) by cen-
trifugation (supplementary methods section 1 and fig. 15,
Supplementary Material online). The column was washed
once with 80% ethanol and DNA was subsequently released
with EBT buffer to a final volume of 40 ml (see supplementary
material section 1, Supplementary Material online). All the
analyses were performed in dedicated ancient DNA labora-
tories where no previous genetic work on Plasmodium had
been carried out, in both Barcelona (extraction of slides in
2016) and Copenhagen (extraction of slides in 2017).
Library Preparation and DNA Sequencing
Shotgun sequencing libraries for the Illumina platform were
prepared using a single-tube protocol for double-stranded
DNA (Carøe et al. 2018), with minor modifications and
improvements as detailed in Mak et al. (2017) (supplemen-
tary methods section 2, Supplementary Material online).
Sequencing was performed at the Natural History Museum
of Denmark on one lane of an Illumina HiSeq2500 instrument
in paired end mode running 125 cycles. This extraction and
amplification process resulted in using all the genetic material
we could source from the available slides.
Sequence Mapping
The sequenced reads were analyzed with FastQC to deter-
mine the quality prior to and after adapter clipping. The 30
read adapters and consecutive bases with low-quality scores
were removed using cutadapt 1.18 (Martin 2011). Reads
shorter than 30 bp and bases with a quality score lower
than 30 were also excluded. To increase the final coverage,
all Plasmodium reads were pooled. As the blood samples had
known coinfection with P. falciparum, we mapped all reads to
both the P. vivax Pv01 reference genome (Auburn et al. 2016)
and the P. falciparum 3D7 reference genome (Gardner et al.
2002). For the small fraction of reads mapping to both refer-
ences (0.4%), we took forward only those reads which showed
a lower edit distance to P. vivax over P. falciparum (supple-
mentary fig. 1, Supplementary Material online). Mapping of
P. vivax reads was then performed with Burrows–Wheeler
Aligner (BWA) (Li and Durbin 2009) 0.7.1 aln (supplementary
methods section 2, Supplementary Material online).
Duplicated reads were deleted using Picard tools 2.18.6
MarkDuplicates. MapDamage 2.0 (Ginolhac et al. 2011) was
applied to check for signatures of postmortem damage at the
ends of the reads to validate the reads were associated with a
historic sample rather than deriving from modern contami-
nation. C to T and G to A substitutions at the 50 ends and 30
ends, respectively, were found to be present at a frequency of
about 2.5% (supplementary fig. 2, Supplementary Material
online); consistent with the age of the sample and in agree-
ment with both the degree of damage previously detected in
the mtDNA reads (Gelabert et al. 2016) and the damage
profile of the human genetic component (supplementary
fig. 3, Supplementary Material online). As a result, the first
two nucleotides of each read were also trimmed.
The newly generated paired-end P. vivax reads were
merged with the sequencing reads generated in 2016
(Gelabert et al. 2016). We refer to the resulting pooled sample
as Ebro-1944. Genotypes were called from the alignment with
GATK v3.7 UnifiedGenotyper (McKenna et al. 2010), using a
minimum base quality of 30 and the standard confidence call
threshold of 50. Genotype calls were filtered further with
VCFtools (Danecek et al. 2011), excluding: 1) heterozygous
calls, 2) calls with depth of coverage<2, 3) calls present in the
telomeres and subtelomeres (Pearson et al. 2016), 4) indels
(supplementary figs. 4 and 5 and table 3, Supplementary
Material online). SNPs were annotated using SnpEff
(Cingolani et al. 2012) for the analysis of variants associated
with drug resistance.
Population Genetics Data Set
The data set used in population genetics analyses comprised
the nuclear sequences of 337 previous published samples of
P. vivax (Hupalo et al. 2016; Pearson et al. 2016; Cowell et al.
2017, 2018; Rodrigues et al. 2018), representing the global
diversity of currently available P. vivax genomes (supplemen-
tary tables 4 and 11, Supplementary Material online).
Sequence reads were aligned against the Sal1 reference
genome (Carlton et al. 2008) with BWA 0.7.1 aln (Li and
Durbin 2009) using default parameters. Duplicated reads
were removed using Picard tools 2.18.6. Reads with mapping
qualities below 30 were removed using SAMtools 1.6 (Li et al.
2009). For analyses requiring incorporation of an out group,
we additionally mapped reads from the P. cynomolgi M strain
(Pasini et al. 2017) against the Sal1 reference genome follow-
ing the same protocol.
We used GATK v3.7 UnifiedGenotyper (McKenna et al.
2010) for SNP calling with a number of adjustments for work-
ing with Plasmodium genomes and ancient DNA. First, we
selected 297 samples that had more than the 70% of the Sal1
reference genome covered and presented more than 3,000
substitutions. Using this filtered data set of high-quality sam-
ples, we called variants using a mapping quality>30, depth of
coverage >20 and a standard call confidence >50. We re-
moved those SNPs that mapped to repetitive regions of the
P. vivax reference genome (Pearson et al. 2016), heterozygous
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calls suggesting possible mixed infections, and SNPs that were
present in less than three samples. The resultant data set
included 131,309 SNPs and 277 strains. We used this catalog
to genotype all remaining samples in the data set. For the
individual genotyping, we called SNPs with GATK v3.7
UnifiedGenotyper as before, removing all heterozygous calls,
and all variants with a minor allele frequency below 0.01%.
The final data set comprised 338 samples and 128,081 SNPs.
The genotypes for Ebro-1944 were called by selecting one
random read that mapped each position of the data set, a
pseudo-haploid calling approach which is advocated for low
coverage aDNA (Mathieson et al. 2015). This resulted in the
Ebro-1944 sequence covering 77,425 of the 128,081 total in-
cluded positions (supplementary table 3, Supplementary
Material online).
Allele-Frequency-Based Measures of Population
Structure
The population genetics data set was filtered for SNPs in high
linkage disequilibrium (LD) using a 60 SNP sliding window,
advancing each time by 10 steps, and removing any SNPs
with a correlation coefficient0.1 with any other SNP within
the window (Chang et al. 2015). This left a pruned data set of
38,358 SNPs for analyses relying on independent SNPs. We
applied PCA to the LD pruned global data set restricted to
only sites covered in all samples (Chang et al. 2015). We ad-
ditionally clustered our pruned data set using the unsuper-
vised clustering algorithm ADMIXTURE 1.3.0 (Alexander et al.
2009) for values of K between 1 and 15. K ¼ 6 provided the
lowest cross-validation error (supplementary fig. 8,
Supplementary Material online and fig. 1c). To evaluate the
relationship of Ebro-1944 to other global strains we calculated
f4 statistics using qpDstat available within AdmixTools
(Patterson et al. 2012). Setting Ebro-1944 as a target, we ex-
plored which strains, grouped by geographic label, share more
alleles with Ebro-1944 relative to every pairwise combination
of modern strain(s) (X and Y) in our reference data set and
relative to P. cynomolgi as an out group: f4 (P. cynomolgi, Ebro-
1944; X, Y) (supplementary fig. 9, Supplementary Material
online).
Inferring Patterns of Allele and Haplotype Sharing
In addition, we applied an unrelated method to explore pat-
terns of allele and haplotype sharing implemented in
CHROMOPAINTER v2 (Lawson et al. 2012). Unlike f-statistics,
this approach does not rely on a user specified topology and
can thus consider the relationship of all strains to all others
collectively. As this approach requires low levels of missing-
ness across comparisons, we filtered the previously described
unpruned population genetics data set for only the positions
present in Ebro-1944 and retained only those samples with
10% missing data (77,420 sites, 218 samples). A schematic of
the workflow is provided in supplementary fig. 7,
Supplementary Material online.
Briefly, CHROMOPAINTER calculates, separately for each
position, the probability that a “recipient” chromosome is
most closely related to a particular “donor” in the data set
under a copying model framework (Li and Stephens 2003).
Here, we use all strains as donors and the equivalent strains as
recipients in an “all-versus-all” painting approach. To cluster
strains, fineSTRUCTURE (Lawson et al. 2012) was applied to
the all-versus-all coancestry matrix to group strains based on
their inferred painting profiles. Given the variable missingness
across the modern strains included in the alignment we
implemented several analyses using the CHROMOPAINTER
unlinked (allele-sharing) implementation, as well as under the
linked CHROMOPAINTER (haplotype-sharing) model. To use
the latter, we performed various levels of imputation followed
the protocol set out by Samad et al (2015) for P. falciparum in
BEAGLE v3.3.2 (Browning and Browning 2013). The consis-
tency of our inference under different imputation and filter-
ing criteria was assessed by linear regression (supplementary
fig. 12, Supplementary Material online). Further details are
provided in supplementary section 4, Supplementary
Material online.
Drug-Resistance Variants Analysis
We used the annotations provided by SnpEff (supplementary
table 7, Supplementary Material online) to identify nonsynon-
ymous mutations in genes previously described as being re-
lated to antimalarial drug resistance and host infectivity
(Cingolani et al. 2012; Gupta et al. 2015; Hupalo et al. 2016;
Pearson et al. 2016; Rodrigues et al. 2018). We also screened a
set of previous described positions that have shown recent
signals of selection in P. vivax populations and all potential
genetic variants found in Ebro-1944, comprising more than
4,000 SNPs (supplementary tables 8–10, Supplementary
Material online).
Phylogenetic Analysis and Data Set
The whole-genome sequences of 15 modern P. vivax samples
and Ebro-1944 were mapped against the PvP01 reference
assembly (Auburn et al. 2016) (supplementary table 5,
Supplementary Material online). These strains were selected
with a focus on the Americas and also to include strains
sampled over a large temporal span as is required for phylo-
genetic tip dating. The main motivation for using the PvP01
reference genome for mapping sequence data for phyloge-
netic analyses stems from this assembly offering a better def-
inition of sub-telomeric genes and repetitive pir genes that
usually lie in recombinant regions, thus providing greater
power to identify and exclude these parts of the genome
(Auburn et al. 2016). After calling variants with GATK version
3.7 UnifiedGenotyper, polymorphisms were further filtered by
selecting only those SNPs with a coverage >1 an average
mapping quality>30, a genotype quality>30, and by remov-
ing heterozygous positions. The exonic positions were then
classified as synonymous and nonsynonymous with SnpEff
(Cingolani et al. 2012).
Our final phylogenetic timeline data set spanned 69 years
(1944–2013) of evolution (supplementary table 5,
Supplementary Material online) across a 34,452 SNP align-
ment. To filter this alignment for only congruent SNPs for
phylogenetic dating we first generated a maximum parsi-
mony phylogeny in MEGA7 (Kumar et al. 2016), evaluating
support for each branch over 100 boot-strap iterations. We
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then screened for homoplasic, sites in the 34,452 SNP align-
ment that do not support the maximum parsimony phylog-
eny, using HomoplasyFinder (Crispell et al. 2019). This led to
the identification of 13,112 homoplasic SNPs, many of which
fell in sub-telomeric regions. All homoplasic sites were subse-
quently removed from the alignment. In this way we screen
and exclude variants from the original alignment that fall in
hypervariable regions, that may arise from inaccurate SNP
calling or postmortem damage, as well as removing regions
that derive from between-lineage genetic recombination or
mixed infections.
Estimating a Timed Phylogeny
To investigate the extent of temporal signal existing in
our homoplasy cleaned timeline alignment, we built a
maximum likelihood phylogenetic tree, without con-
straining tip-heights to their sampling times, using
RaxML (Stamatakis 2014). These trees were robust to
the inclusion of SNPs called at different depths (supple-
mentary fig. 13, Supplementary Material online). After
rooting the tree on the P. cynomolgi genome, we com-
puted a linear regression between root-to-tip distance
and sampling time using the roototip function from
BactDating (Didelot et al. 2018). To further confirm the
presence of a significant temporal signal, we assessed the
significance of this regression following 10,000 steps of
date randomization (fig. 3b). After confirmation of tem-
poral signal in the data set, substitution rates were esti-
mated by running a tip-calibrated inference using Markov
chain Monte Carlo (MCMC) sampling in BEAST 2
(Bouckaert et al. 2014). The best-fit nucleotide substitu-
tion model was estimated as TN93 following evaluation of
all possible substitution models in BModelTest
(Bouckaert and Drummond 2017). To minimize prior
assumptions about demographic history we tested three
possible demographic models: the coalescent constant,
coalescent exponential, and coalescent Bayesian skyline.
In each case we set a log-normal prior on a relaxed evo-
lutionary clock as well as testing under a strict clock
model.
To calibrate the tree using tip-dates only, we applied flat
priors (i.e. uniform distributions) for the substitution rate
(1.10E12–1.10E2 substitutions/site/year), as well as for the
age of any internal node in the tree. We ran five independent
chains in which samples were drawn every 50,000 MCMC
steps from a total of 500,000,000 steps, after a discarded
burn-in of 10,000,000 steps. Convergence to the stationary
distribution and sufficient sampling and mixing were checked
by inspection of posterior samples (effective sample size
>200) in Tracer v1.6. The best-fit model was selected based
on evaluation of both the median likelihood value of the
model and the maximum likelihood estimator following
path sampling (Baele et al. 2012) (supplementary fig. 14
and table 6, Supplementary Material online).
Supplementary Material
Supplementary data are available at Molecular Biology and
Evolution online.
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